Press release - 30/03/2022 CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV CureVac N.V. a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-gsk-start-clinical-development-second-generation-covid-19-vaccine-candidate-cv2cov
Press release - 01/03/2022 CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer® The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics. CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer®. Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbH.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-gruendet-tochtergesellschaft-zur-weiterentwicklung-des-rna-printer
Press release - 10/02/2022 CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that it has dosed the first participant in a Phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate, CVSQIV, developed in collaboration with GSK.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-doses-first-participant-phase-1-study-multivalent-influenza-vaccine-candidate-based-second-generation-mrna-backbone-deve
Press release - 10/01/2022 Algorithm identifies cancer drivers Genetic alterations that promote the development and spread of tumors are difficult to identify. This is especially true for mutations in the non-protein-coding regions of the genome, which include all important regulatory sequences. Scientists at the German Cancer Research Center have now published an algorithm that detects cancer drivers in both the protein-coding and non-coding regions of the genome.https://www.gesundheitsindustrie-bw.de/en/article/press-release/algorithm-identifies-cancer-drivers
Press release - 29/11/2021 Tracking down resistant cancer cells In multiple myeloma, a cancer of the bone marrow, relapse almost always occurs after treatment. Initially, most patients respond well to therapy. However, as the disease progresses, resistant cancer cells spread in the bone marrow, with fatal consequences for the patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracking-down-resistant-cancer-cells
Press release - 23/11/2021 Multi-peptide vaccine against SARS-CoV-2 shows strong T-cell immune response At the University Hospital Tübingen, clinical evaluation of an in-house developed vaccine (CoVac-1) against SARS-CoV-2 was started in November 2020 under the direction of Prof. Dr. Juliane Walz in the CCU Translational Immunology of the Medical Clinic (Medical Director Prof. Dr. Helmut Salih). Now the results of the Phase I study are available and demonstrate a potent activation of the T-cell response against the coronavirus.https://www.gesundheitsindustrie-bw.de/en/article/press-release/multi-peptide-vaccine-against-sars-cov-2-shows-strong-t-cell-immune-response
Press release - 12/10/2021 CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-shift-focus-covid-19-vaccine-development-second-generation-mrna-technology
Press release - 30/08/2021 CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the publication entitled “Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model” in the peer-reviewed Journal of Hepatology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-preclinical-data-demonstrates-significant-reduction-liver-fibrosis-mrna-therapeutic
Press release - 16/06/2021 CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced results of the second interim analysis of its international pivotal Phase 2b/3 study in approximatively 40,000 subjects (the HERALD study) of CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-provides-update-phase-2b3-trial-first-generation-covid-19-vaccine-candidate-cvncov
Press release - 30/03/2021 Celonic and Curevac announce agreement to manufacture over 100 Million doses of Curevac's Covid-19 vaccine candidate, CVnCoV CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on mRNA and Celonic Group, a premium biopharmaceutical Contract Development and Manufacturing Organization specializing in the development and production of Advanced Therapy Medicinal Products and mammalian cell line-expressed bio-therapeutics, announced their partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV.https://www.gesundheitsindustrie-bw.de/en/article/press-release/celonic-and-curevac-announce-agreement-manufacture-over-100-million-doses-curevacs-covid-19-vaccine-candidate-cvncov
Press release - 23/03/2021 CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant (South African Variant) in Preclinical Challenge Study CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 and a strain of the original SARS-CoV-2 B1 lineage (BavPat1) in a transgenic mouse model.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-covid-19-vaccine-candidate-cvncov-demonstrates-protection-against-sars-cov-2-b1351-variant-south-african-variant-precli
Press release - 04/03/2021 CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Novartis AG announced today that they have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV. Preparations for the start of production, technology transfers and test runs are already underway. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-novartis-sign-initial-agreement-manufacturing-covid-19-vaccine-candidate-cvncov
Press release - 24/02/2021 Supposedly "silent" mutation with serious consequences So-called silent mutations have no effect on the composition of a protein. They are therefore not considered to promote cancer. However, scientists from the German Consortium for Translational Cancer Research (DKTK), partner site Essen, now describe in a case of kidney cancer an overlooked silent mutation with a major impact on prognosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/supposedly-silent-mutation-serious-consequences
Press release - 11/01/2021 CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-covid-19-vaccine-candidate-cvncov-demonstrated-efficient-protection-non-human-primates-during-sars-cov-2-challenge-infe
Press release - 07/01/2021 CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV Bayer has signed a collaboration and services agreement with CureVac, a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid. Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-bayer-join-forces-covid-19-vaccine-candidate-cvncov
Press release - 16/11/2020 European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), reports the European Commission’s announcement that tomorrow it will authorize an Advanced Purchase Agreement for CureVac´s mRNA-based COVID-19 vaccine candidate, CVnCoV.https://www.gesundheitsindustrie-bw.de/en/article/press-release/european-commission-announces-tomorrow-it-will-authorize-agreement-curevac-supply-405-million-doses-mrna-based-covid-19-vaccine
Press release - 02/11/2020 CureVac Reports Positive Interim Phase 1 Data for its COVID-19 Vaccine Candidate, CVnCoV CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive interim data from its ongoing Phase 1 dose-escalation study evaluating the safety, reactogenicity and immunogenicity of CVnCoV, its investigational SARS-CoV-2 vaccine candidate. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-reports-positive-interim-phase-1-data-its-covid-19-vaccine-candidate-cvncov
Press release - 23/10/2020 CureVac Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, CVnCoV CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced data from preclinical studies of its investigational SARS-CoV-2 vaccine candidate, CVnCoV, in mice and hamsters.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-reports-positive-preclinical-data-its-covid-19-vaccine-candidate-cvncov
Press release - 07/10/2020 Joining forces against SARS-CoV-2 Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced an agreement to serve as CDMO partner for BioNTech. As an initial project, Rentschler Biopharma will be responsible for key aspects of cGMP (current good manufacturing practice) drug substance manufacturing of BNT162b2, the mRNA-based vaccine against SARS-CoV-2 that is being developed by Pfizer and BioNTech.https://www.gesundheitsindustrie-bw.de/en/article/press-release/joining-forces-against-sars-cov-2
Press release - 17/06/2020 CureVac Receives Regulatory Approval from German and Belgian Authorities to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Belgium.https://www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-Receives-Regulatory-Approval-from-German-and-Belgian-Authorities-to-Initiate-Phase-1-Clinical-Trial-of-its-SARS-CoV-2-Va
Press release - 15/06/2020 German Federal Government invests 300 Million Euros in CureVac The German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp, SAP co-founder and co-founder of the investment company dievini Hopp BioTech holding GmbH & Co. KG, announced today that the Federal Republic of Germany will invest 300 million Euros in the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical development of mRNA-based drugs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/german-federal-government-invests-300-million-euros-curevac
Vaccine development - 02/06/2020 CureVac as a pioneer of mRNA technology – what is behind the novel COVID-19 vaccine? All eyes are on vaccines against the coronavirus. The Tübingen-based company CureVac is doing pioneering work in this field, and intends to initiate clinical testing of its lead vaccine candidate in June. At the same time, Curevac is manufacturing the material for this vaccine candidate. But that’s not all: the novel mRNA technology also has the potential to revolutionise the treatment of cancer and metabolic diseases. What makes the method so…https://www.gesundheitsindustrie-bw.de/en/article/news/curevac-als-pionier-der-mrna-technologie-was-steckt-hinter-dem-neuartigen-covid-19-impfstoff
Press release - 14/05/2020 CureVac´s Optimized mRNA Platform Provides Positive Pre-Clinical Results at Low Dose for Coronavirus Vaccine Candidate CureVac AG, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimized mRNA, today announced positive pre-clinical results at a low dose for its lead vaccine candidate against the novel Coronavirus (SARS-CoV-2).https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevacs-coronavirus-impfstoffkandidat-zeigt-dank-optimierter-mrna-plattform-positive-praeklinische-ergebnisse-bei-niedriger-dos
Press release - 16/03/2020 CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide CureVac AG, a clinical stage biopharmaceutical company pioneering mRNA-based drugs for vaccines and therapeutics, confirmed today that internal efforts are focused on the development of a coronavirus vaccine with the goal to reach, help and to protect people and patients worldwide.https://www.gesundheitsindustrie-bw.de/en/article/press-release/CureVac-focuses-on-the-development-of-mRNA-based-coronavirus-vaccine-to-protect-people-worldwide
Press release - 11/03/2020 Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that company founder and Chairman of the Supervisory Board Ingmar Hoerr is replacing Daniel Menichella in his function as Chief Executive Officer (CEO). https://www.gesundheitsindustrie-bw.de/en/article/press-release/Company-Founder-Ingmar-Hoerr-Succeeds-Daniel-Menichella-as-CEO-of-CureVac-AG